SCHEMBL8925427

SCHEMBL8925427

O=C(CBr)c1cccc(N2CCOCC2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.52
IRAK4 Q9NWZ3 3/20 0.47
KIF18A Q8NI77 2/20 0.46
GAA P10253 1/20 0.46
PKM P14618 1/20 0.42
HSD11B1 P28845 1/20 0.41
PIK3CB P42338 2/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 1/20 0.41
FLT3 P36888 1/20 0.41
PIK3CA P42336 2/20 0.40
HTT P42858 2/20 0.40
KMO O15229 1/20 0.40
PIK3CD O00329 1/20 0.40
RAB9A P51151 1/20 0.40
ATM Q13315 1/20 0.40
PLOD2 O00469 1/20 0.40
PLOD3 O60568 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8923789 0.83 HSD17B14 (0.53) HSD11B1KDM4EALDH1A1PLOD2PLOD3
SCHEMBL1779262 0.82 KMO (0.55) IRAK4KIF18AGAAPKMHSD11B1
SCHEMBL29483989 0.82 KMO (0.55) IRAK4KIF18AGAAPKMHSD11B1
SCHEMBL2815393 0.82 IRAK4 (0.60) IRAK4KIF18AGAAPKMHSD11B1
SCHEMBL26618183 0.82 KIF18A (0.44) KIF18AHSD11B1
SCHEMBL12734079 0.81 IRAK4 (0.53) IRAK4KIF18AGAAPKMHSD11B1
Hydrochloric Acid SCHEMBL22234574 0.81 KMO (0.54) IRAK4KIF18AGAAPKMHSD11B1
SCHEMBL30642987 0.80 IRAK4 (0.58) IRAK4KIF18AGAAHSD11B1PIK3CB
SCHEMBL2552790 0.80 IRAK4 (0.58) IRAK4KIF18AGAAHSD11B1PIK3CB
Hydrochloric Acid SCHEMBL26695120 0.79 IRAK4 (0.52) IRAK4KIF18AGAAPKMHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382889-A1 COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-11-30 US disclosed
US-20230382889-A1 COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-11-30 US disclosed
WO-2023212240-A1 COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-11-02 WO disclosed
US-5639770-A SUPEROXIDE INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-06-17 US disclosed
EP-0600092-A1 THIAZOLE DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382889-A1 COMPOUNDS FOR INHIBITING KIF18A KIF18A, KIF18B, KIF2C GSK3B 1097/4885IRAK4 3246/4885KIF18A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.